Evaluation of 18F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment

Journal of Thoracic Oncology

Volumn 4, Issue 10, 2009, Pages 1226-1230

  Aukema, Tjeerd S ^a   Valdés Olmos, Renato A ^a   Klomp, Houke M ^a   Teertstra, Hendrik J ^a   Belderbos, José S A ^a   Vogel, Wouter V ^a   Baas, Paul ^a   Burgers, Sjaak A ^a   Van Den Heuvel, Michel M ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Diagnosis; Fast track assessment.; Lung Neoplasms; Positron Emission Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIOPSY; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; INFORMATION; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NETHERLANDS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARD; THORAX RADIOGRAPHY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; LUNG SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349676121     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b2b782     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Selby P, Gillis C, Haward R. Benefits from specialised cancer care. Lancet 1996;348:313-318.
3. Conron M, Phuah S, Steinfort D, Dabscheck E, Wright G, Hart D. Analysis of multidisciplinary lung cancer practice. Intern Med J 2007; 37:18-25.
4. Rajasekaran AB, Silvey D, Leung B, et al. Effect of a multidisciplinary lung investigation day on a rapid access lung cancer service. Postgrad Med J 2006;82:414-416.
5. Gould MK, Ghaus SJ, Olsson JK, Schultz EM. Timeliness of care in veterans with non-small cell lung cancer. Chest 2008;133:1167-1173.
6. Moody A, Muers M, Forman D. Delays in managing lung cancer. Thorax 2004;59:1-3.
7. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006;24:1800-1806.
8. Plathow C, Aschoff P, Lichy MP, et al. Positron emission tomography/ computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer-initial results. Invest Radiol 2008;43:290-297.
9. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001;19:111-118.
10. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943-1951.
11. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-1393.
12. Lowe VJ, Hoffman JM, Delong DM, Patz EF, Coleman RE. Semiquan-titative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-1776.
13. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-1723.
14. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-536.
15. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507. (Pubitemid 36706537)
16. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229: 526-533.
17. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-1019.
18. Konishi J, Yamazaki K, Tsukamoto E, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70:500-506.
19. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77.
20. Takamochi K, Yoshida J, Murakami K, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235-242.
21. Salomaa ER, Sallinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005;128:2282-2288.